Strictly for in vitro laboratory research and analytical identification only. Not for human or veterinary use.

Adalank is marketed as a modified version of Selank, a synthetic neuropeptide researched for its potential effects on anxiety, stress and brain function.

Adalank is marketed for potential neurological effects, including:

•Anxiety support – Potential calming effects.

•Stress management – Investigated by analogy with Selank.

•Mental clarity – Marketed for focus and concentration.

•Cognitive function – Potential effects on memory and brain signalling.

•Neuropeptide activity – Intended to influence pathways associated with Selank.

Adalank is commonly described as having two chemical modifications:

N-terminal acetylation.

C-terminal amidation.

These modifications are intended to make the peptide more resistant to enzymatic breakdown. Whether they actually improve its duration or effectiveness has not been demonstrated.

Its safety profile is unknown because adequate human studies have not been conducted. Potential risks include unexpected neurological effects, allergic reactions and unknown long-term effects.

It should not be assumed safe for human use simply because Selank has been studied.

Strictly for in vitro laboratory research and analytical identification only. Not for human or veterinary use.

Wolverine Stack is a name commonly used in the peptide research market for a combination of two experimental peptides:

BPC-157

A synthetic peptide containing 15 amino acids.

Being investigated for tendon and ligament repair.

Animal studies suggest potential benefits for muscle and tissue healing.

Also being researched for gastrointestinal protection.

TB-500

A synthetic peptide fragment related to thymosin beta-4.

Associated with cellular repair processes.

Being investigated for wound healing and tissue regeneration.

Has shown promising results in some laboratory and animal research.

There are some promising early findings, but important limitations:

The combination has not been adequately tested in human clinical trials.

There is no established safe or effective human dose.

Long-term safety is unknown.

Neither peptide is an approved medicine in Australia. 

Strictly for in vitro laboratory research and analytical identification only. Not for human or veterinary use.

Cagrilintide is an experimental weight-loss peptide developed by Novo Nordisk. It is designed to reduce appetite, increase feelings of fullness and help people consume fewer calories.

It works differently from traditional GLP-1 medications such as Ozempic.

Cagrilintide mimics a naturally occurring hormone called amylin, which is released by the pancreas after eating.

It works by:

Suppressing appetite: Helps reduce hunger.

Increasing fullness: Makes you feel satisfied for longer.

Slowing gastric emptying: Slows how quickly food leaves the stomach.

Reducing food intake: May help reduce overall calorie consumption.

Supporting weight loss: Has demonstrated meaningful weight reduction in clinical trials.

Clinical trials have reported:

Nausea

Vomiting

Constipation

Diarrhoea

Abdominal discomfort

Cagrilintide is primarily an appetite-control peptide, not a direct fat-burning peptide.

Cagrilintide is not an approved medicine for general use. 

Strictly for in vitro laboratory research and analytical identification only. Not for human or veterinary use.

Eloralintide (also known as LY3849891) is an experimental peptide-based medication being developed for weight management and metabolic health.

Unlike Tirzepatide and Retatrutide, Eloralintide works primarily by targeting the amylin receptor pathway.

Eloralintide is an amylin analogue. Amylin is a hormone naturally released alongside insulin after eating.

It may help by:

•Reducing appetite – Helps regulate hunger signals.

•Increasing fullness – May make you feel satisfied for longer.

•Reducing food intake – May reduce overall calorie consumption.

•Supporting weight loss – Being investigated as a potential obesity treatment.

•Metabolic regulation – May influence glucose and appetite-related pathways.

Reported side effects include:

Nausea.

Fatigue.

Headaches.

Reduced appetite.

Vomiting.

Injection-site reactions.

Eloralintide remains investigational and is undergoing Phase 3 clinical trials. It is not an approved weight-loss medication in Australia.

Strictly for in vitro laboratory research and analytical identification only. Not for human or veterinary use.

FOXO4-DRI is designed to interfere with the interaction between two proteins:

•FOXO4: A protein involved in cell survival, stress responses and ageing-related processes.
•p53: A protein that helps regulate cell growth, DNA damage responses and cell death.

Important concerns:

No established human dose.

No published human clinical trials.

Long-term effects are unknown.

Interfering with p53 could have unintended effects because it plays an important role in cancer protection.

Removing senescent cells may also interfere with some normal repair processes.

It is not an approved medicine in Australia.

Strictly for in vitro laboratory research and analytical identification only. Not for human or veterinary use.

KLOW 80mg is a four-peptide research blend marketed for skin, tissue repair, recovery and inflammation research.

It is not one individual peptide. It combines four different compounds in one vial.

•GHK-Cu – 50mg

Copper peptide studied for collagen production, skin repair and wound healing.

•BPC-157 – 10mg

Studied in preclinical research involving tendon, muscle and gastrointestinal tissue repair.

•TB-500 – 10mg

Studied for cellular migration, tissue repair and recovery processes.

•KPV – 10mg

Studied for anti-inflammatory activity, particularly in experimental gut inflammation.

These are research interests, not proven benefits of KLOW. The complete four-peptide combination has not been established as safe or effective in human clinical trials. It is not an approved treatment for human use.

Strictly for in vitro laboratory research and analytical identification only. Not for human or veterinary use.

Retatrutide (also known as Reta or LY3437943) is an experimental peptide medication being developed by Eli Lilly, primarily for weight loss, obesity and metabolic health.

It has attracted significant attention because it targets three different hormone receptors, rather than one or two like existing weight-loss medications.

Retatrutide is known as a triple agonist because it activates:

•GLP-1: Helps reduce appetite, slow stomach emptying and regulate blood sugar.

•GIP: Helps regulate insulin release and glucose metabolism.

•Glucagon: May increase energy expenditure and influence how the body uses stored energy.

Potential benefits being researched:

Significant weight reduction.

Reduced appetite and food cravings.

Improved blood sugar regulation.

Improved metabolic health.

Reduced body fat.

Potential improvements in obesity-related conditions.

Reported side effects in clinical trials include:

Nausea

Vomiting

Diarrhoea

Constipation

Reduced appetite

Increased heart rate

Long-term safety is still being investigated.

Retatrutide is not approved by Australia's TGA. It remains an investigational medication.

Strictly for in vitro laboratory research and analytical identification only. Not for human or veterinary use.

Selank is a synthetic peptide originally developed in Russia and researched primarily for its potential effects on anxiety, stress, mood and cognitive function.

It is often marketed as a neuropeptide or nootropic peptide because of its proposed effects on brain signalling.

Selank is a seven-amino-acid peptide derived from a naturally occurring immune-system peptide called tuftsin.

Researchers have investigated several potential effects:

•Anxiety reduction – Potential calming and anti-anxiety effects.

•Stress management – Possible effects on the body's stress response.

•Cognitive function – Being investigated for memory and concentration.

•Mood regulation – Potential influence on neurotransmitter activity.

•GABA activity – May influence GABA-related brain signalling.

Potential concerns include:

Headaches.

Nasal irritation with nasal formulations.

Drowsiness.

Allergic or immune reactions.

Unknown long-term effects.

Selank is not an approved therapeutic medicine in Australia. Its human safety, effectiveness and appropriate dosing have not been adequately established. Products sold as research peptides should not be assumed safe for human use.